Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liquidia Technologies Inc.

This article was originally published in Start Up

Executive Summary

Liquidia Technologies is developing nanoparticles whose size, shape, particle cargo, and target specificity can be exquisitely controlled. In order to create its particles, Liquidia borrows fabrication methods originally developed by the electronics industry. I

You may also be interested in...



Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.

IPO Update: Returns Ride Rollercoaster Into Mid-Year As More Biopharmas Take The Plunge

Returns for the 36 biopharma firms that went public in the first half of 2018 – including 14 in June alone – averaged 20.9%, stabilizing after a dip earlier in the year. But while drug developer returns have been on a rollercoaster ride, they're doing better than broader stock indices.

TransGenex Nanobiotech Inc.

TransGenex Nanobiotech is taking a multi-pronged approach to building a nanotechnology company. In the short term, the company is generating revenue from sales of its custom nanoparticles and its Nanogene reagents that can be used to deliver genes to cells. It is also using its technology to develop diagnostic platforms, especially for lung and ovarian cancer. Finally, TransGenex plans to develop its own novel drug candidates. It's focusing first on products with anti-inflammatory properties, which could find application in asthma as well as several cancers.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL021103

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel